Navigation Links
EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases
Date:10/17/2007

of Maria S. Gawryl, 53, as Senior Director and program executive for the Alpha 7 initiative. Dr. Gawryl has more than 20 years of pharmaceutical experience with companies such as RenaMed Biologics, Biopure Corporation, Baxter and Bioscience associates, as well as research experience at academic institutions such as Harvard and Yale University School of Medicine. She has executed and completed numerous multinational clinical trials and over 250 preclinical studies. She holds a Bachelor of Science in Chemistry and Mathematics from Antioch College, a Ph.D. in Immunology/Biomedical Sciences from the University of Connecticut and completed post-doctoral research at Rush Medical College in Chicago.

"Our Company is continuing to make steady progress across all programs of our pipeline, so we are privileged to have such an experienced clinical pharmacologist join our teams to further advance these important programs into later-stage clinical trials" stated Kees Been, EnVivo's President and Chief Executive Officer.

EnVivo Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders including, Alzheimer's disease, Parkinson's disease and Huntington's disease. The company's lead programs include a Nicotinic Acetylcholine Receptor Agonist Program (alpha-7) for Alzheimer's disease and Schizophrenia, a Histone Deacetylase Inhibitor (HDACi) Program for Huntington's disease and several other programs such as the EVP2442 program for neuro-protection and the PDE10 inhibitor and gamma-secretase modulator programs. More information about EnVivo is available at http://www.envivopharma.com .


'/>"/>
SOURCE EnVivo Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013 The potential of ... delivery of therapeutic agents has been receiving undeniable attention ... showing significant promise. The crucial formulation considerations for orally ... play a major role in the efficiency of pulmonary ... development of new formulation techniques and devices in recent ...
(Date:5/23/2013)... DIEGO , May 23, 2013 Neurocrine Biosciences, ... Kevin Gorman , President and Chief Executive Officer ... 38 th Annual dbAccess Health Care Conference in Boston.   ... May 30 at 11:20 a.m. Eastern Time / 8:20 a.m. ... accessed on the Company,s website at http://www.neurocrine.com . ...
(Date:5/23/2013)... , May 23, 2013  MGC Diagnostics Corporation ... global medical technology company, today scheduled a conference call ... of fiscal year 2013, ended April 30, 2013. The ... May 30, 2013. The Company will report financial results ... the markets close on Thursday, May 30, 2013. ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2
... 22, 2011 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has accepted for review ... Injection for Subcutaneous Use for the prevention of gout ... Prescription Drug User Fee Act (PDUFA), the goal for ...
... Endoscopy, Inc.,s (OTCPK: SNDY) is pleased to announce that ... of $73,895.  Solos Endoscopy has consummated agreements which resulted ... Three Months period ending September 30, 2011.  The signed ... reduction of ongoing expenses by approximately $40,000 per quarter. ...
Cached Medicine Technology:Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8Solos Endoscopy Finishes the 3rd Quarter With a Net Profit 2
(Date:5/25/2013)... York, New York (PRWEB) May 25, 2013 ... who allegedly suffered serious, life-threatening episodes of internal bleeding while ... litigation underway in U.S. District Court, Southern District of Illinois, ... the Court’s website, 818 Pradaxa side effect claims had ... 2013. That’s up from 705 claims reported by the ...
(Date:5/25/2013)... NY (PRWEB) May 25, 2013 On ... to brain cancer research and advocacy, comments on a ... Physics, that shows incorporating cold atmospheric plasma into brain ... , According to a Science Daily ... Physics (MPE), biologists and physicians demonstrated the “synergistic effect ...
(Date:5/25/2013)... May 25, 2013 Dr. Farooq Ashraf, ... clinic in Dubai, has announced his practice’s adoption of ... the only FDA-cleared femtosecond laser proven with more than ... and precision of LASIK. , “We are happy to ... Femtosecond Laser at our Dubai LASIK practice,” Ashraf said ...
(Date:5/25/2013)... CA (PRWEB) May 25, 2013 The Slim ... its effectiveness and results. This is due to the highly ... adhesive patches. Slim weight patch offers an extra 2 months ... loss, fitness goals and get the body you desire faster ... Patch Official Website , With Slim weight patch consumers ...
(Date:5/25/2013)... For college students, few events can ... are turning to prescription stimulants like Adderall to ... on this, go to http://www.sciencedaily.com/releases/2013/05/130501145151.htm . , ... students who pick up Adderall, “just to help ... a physical and psychological dependency. While initially they ...
Breaking Medicine News(10 mins):Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2
... threshold of a new era based on better understanding ... each other. There is great potential for exploiting the ... to develop new drugs that act more specifically without ... nature. , A recent workshop on Biosupramolecular Chemistry ...
... The National Lung Cancer Partnership announced today ... Foundation, the Oncology Nursing Society Foundation and the International ... the mission to increase opportunities for lung cancer researchers ... Lung cancer is the leading cancer killer of men ...
... Study found adults ate worse than children did in ... Members of poor households in which it is consistently ... nutritionally risky diets, Canadian researchers reveal. , The new ... directly translates into poor nutrition. It also suggests that ...
... A new take on pilots, health,workplace injuries connected ... studies to be presented at Preventive Medicine 2008,the ... 2008 in Austin, Texas., Long-Haul Flights May ... investigated if acute stress phenomena associated with,frequent take ...
... Lady Laura Bush,today visited the Maamobi Polyclinic in ... two interventions being implemented by AED to control,malaria., ... with Ghana,s commercial,sector to increase the availability and ... in Ghana and five,other sub-Saharan African countries, and ...
... working together to provide dental offices with exposure, to ... Optimizer(R) and other Sikka Software products that assist, dentists and ... financial performance of their practice. Dental Economics will utilize,Sikka Software,s ... ...
Cached Medicine News:Health News:New understanding of how big molecules bind will lead to better drugs, synthetic organic materials 2Health News:New understanding of how big molecules bind will lead to better drugs, synthetic organic materials 3Health News:National Lung Cancer partnership 2Health News:Poverty Drains Nutrition From Family Diet 2Health News:Poverty Drains Nutrition From Family Diet 3Health News:News Briefs from Preventive Medicine 2008 2Health News:News Briefs from Preventive Medicine 2008 3Health News:First Lady Laura Bush Visits AED/Netmark Malaria-Control Project in Ghana 2Health News:Sikka Software and Dental Economics Announce Alliance 2
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... moderate viscosity and density. Proven ergonomic design reduces hand fatigue, prevents injury. ... (ul) ... 2~5 Imprecision(%) ... 0.01 Dimensions: ...
... the range from 2ul to 5000ul. Fills ... design prevents inadvertent volume change. Novel hand ... pipette is autoclavable at 121C(250F). To prevent ... Suitable for one-handed operation. Auto or Normal ...
... fully adjustable, air-displacement pipette with a patented ... member of the Pipetman family, sharing many ... precision. We also added a number of ... Eight models cover the full range of ...
Medicine Products: